๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Rezdiffra Pregnancy and Lactation Registry NCT07541469n/a1 site๐Ÿ“ West Conshohocken Madrigal Pharmaceuticals, Inc. ยท Tests: Rezdiffra Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants NCT07512427Phase 1, Phase 21 site๐Ÿ“ Miami OPKO Health, Inc. ยท Tests: OPK-88006, Placebo A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH) NCT07732400Phase 1, Phase 23 sites๐Ÿ“ Chandler๐Ÿ“ Lady Lake๐Ÿ“ Auckland Kriya Therapeutics, Inc. ยท Tests: VV-14303 A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH NCT06419374Phase 3330 sites๐Ÿ“ Birmingham๐Ÿ“ Homewood๐Ÿ“ Chandler Hoffmann-La Roche ยท Tests: Pegozafermin, Placebo Digoxin In NASH (CODIN) NCT06588699Phase 22 sites๐Ÿ“ New Haven๐Ÿ“ New Haven Yale University ยท Tests: Digoxin, Placebo Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease NCT07058155Phase 41 site๐Ÿ“ Cleveland The Cleveland Clinic ยท Tests: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), โ€ฆ A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment NCT07807059Phase 11 site๐Ÿ“ Chengdu Fujian Shengdi Pharmaceutical Co., Ltd. ยท Tests: HRS-4729 Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH NCT07795164Phase 39 sites๐Ÿ“ North Little Rock๐Ÿ“ Fountain Valley๐Ÿ“ Fresno Altimmune, Inc. ยท Tests: Pemvidutide, Placebo A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) NCT07145151Phase 21 site๐Ÿ“ Beijing The United Bio-Technology (Hengqin) Co., Ltd. ยท Tests: UBT251, Placebo A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD NCT07527910Phase 29 sites๐Ÿ“ Tucson๐Ÿ“ Coronado๐Ÿ“ Pasadena Regeneron Pharmaceuticals ยท Tests: ALN-PNP, Tirzepatide, Placebo A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH NCT07581951Phase 31 site๐Ÿ“ Beijing Haisco Pharmaceutical Group Co., Ltd. ยท Tests: HSK31679, Placebo Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH) NCT07013916NA2 sites๐Ÿ“ London๐Ÿ“ London Queen Mary University of London ยท Tests: fructose, glucose Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD NCT07632677n/a22 sites๐Ÿ“ Bengbu๐Ÿ“ Hefei๐Ÿ“ Wuhu The Affiliated Nanjing Drum Tower Hospital of Nanjing Univeโ€ฆ ยท Tests: iLivTouch (Vibration-controlled transient elastography) A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) NCT06318169Phase 3370 sites๐Ÿ“ Birmingham๐Ÿ“ Chandler๐Ÿ“ Flagstaff Hoffmann-La Roche ยท Tests: Pegozafermin, Placebo Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD NCT07877272n/a1 site๐Ÿ“ Mรผnster University Hospital Muenster ยท Tests: Non-invasive MASLD and portal hypertension assessment, Single-session endohepatology assessment Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity NCT07803809Phase 11 site๐Ÿ“ Kunming Shanghai Minwei Biotechnology Co., Ltd ยท Tests: MWN105 1, MWN105 2, MWN105 3, Placebo Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo) NCT07330830n/a3 sites๐Ÿ“ Cayenne๐Ÿ“ Pointe-ร -Pitre๐Ÿ“ Saint-Denis Centre Hospitalier Universitaire de la Guadeloupe Rezdiffraยฎ With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis NCT07848191Phase 416 sites๐Ÿ“ Chandler๐Ÿ“ North Little Rock๐Ÿ“ Coronado Madrigal Pharmaceuticals, Inc. ยท Tests: Rezdiffra, Resmetirom, ACTOS/pioglitazone, FARXIGA/dapagliflozin Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) NCT07631637Phase 216 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Tucson Regeneron Pharmaceuticals ยท Tests: ALN-CIDEB, Placebo Study of Resmetirom in Children and Adolescents With MASH NCT07763015Phase 21 site๐Ÿ“ Indianapolis Madrigal Pharmaceuticals, Inc. ยท Tests: Resmetirom A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis NCT07660848Phase 22 sites๐Ÿ“ Beijing๐Ÿ“ Zhengzhou Fujian Shengdi Pharmaceutical Co., Ltd. ยท Tests: HRS-4729 Injection, HRS9531 Injection, HRS-4729 Injection Placebo, HRS9531 Injection Placebo Digital Early Warning System for Acute Lung Injury in Liver Surgery NCT07070362n/a4 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Chongqing Beijing Tsinghua Chang Gung Hospital A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH NCT07221188Phase 366 sites๐Ÿ“ Arcadia๐Ÿ“ Covina๐Ÿ“ Los Angeles GlaxoSmithKline ยท Tests: Efimosfermin Alfa, Placebo Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR) NCT07737340n/a11 sites๐Ÿ“ Ankara๐Ÿ“ Adana๐Ÿ“ Adana YaลŸar Bayฤฑndฤฑr, MD ยท Tests: FibroScan (Transient Elastography), Hepatobiliary Ultrasonography (USG), Clinical and Laboratory Monitoring Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study NCT07188220n/a2 sites๐Ÿ“ Barcelona๐Ÿ“ Barcelona Fundaciรณ Institut de Recerca de l'Hospital de la Santa Creuโ€ฆ A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition NCT05519475Phase 271 sites๐Ÿ“ Flagstaff๐Ÿ“ Peoria๐Ÿ“ Tucson Regeneron Pharmaceuticals ยท Tests: ALN-HSD, Placebo Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH NCT06813508n/a1 site๐Ÿ“ Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH NCT06528314Phase 3345 sites๐Ÿ“ Birmingham๐Ÿ“ Dothan๐Ÿ“ Chandler Akero Therapeutics, Inc ยท Tests: Efruxifermin, Placebo A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) NCT07325526Phase 227 sites๐Ÿ“ Chandler๐Ÿ“ Coronado๐Ÿ“ La Mesa Boehringer Ingelheim ยท Tests: BI 3802876, Placebo Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant NCT07685353n/a1 site๐Ÿ“ New Delhi Institute of Liver and Biliary Sciences, India
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy